Regen BioPharma Reports Financial Results for Quarter Ending December 31, 2024

Regen BioPharma, Inc. reported its financial results for the quarter ending December 31, 2024, revealing a net revenue of $59,065, consistent with the same period in 2023. The revenue included $27,425 from related parties, specifically from a licensing agreement with Zander Therapeutics, Inc., and $31,640 from Oncology Pharma, Inc. Operating expenses for the quarter decreased significantly to $120,443 from $181,847 in the prior year, primarily due to reduced consulting and professional fees, which fell from $106,900 to $84,626. The company reported a loss from operations of $61,378, an improvement from the $122,782 loss recorded in the same quarter of 2023.

Despite the reduction in operating losses, Regen BioPharma experienced a substantial increase in net loss, which totaled $515,384 for the quarter, compared to a net loss of $144,913 in the previous year. This increase was largely attributed to a derivative loss of $416,016 recognized during the quarter. The company's total other expenses also rose significantly, from $22,151 in 2023 to $454,007 in 2024, driven by higher interest and amortization expenses.

In terms of operational developments, Regen BioPharma's working capital deficit increased to $5,696,776 as of December 31, 2024, up from $5,235,105 at the end of September 2024. The company reported cash and cash equivalents of $135 at the end of the quarter, a decrease from $124,497 a year earlier. The company continues to rely on financing activities, generating $65,799 in cash from notes payable during the quarter, compared to $165,797 in the same period of 2023.

Regen BioPharma is actively engaged in the development of regenerative medical applications, focusing on small molecules that modulate immune responses for oncology and autoimmune diseases. The company is in the early stages of product development and has not yet received FDA approval for any of its therapies. The management has indicated that significant professional and research costs are expected to continue, and the company will need to secure additional funding to maintain operations and advance its development plans.

Looking ahead, Regen BioPharma faces substantial challenges, including recurring losses and negative cash flows since inception. The company has expressed doubt about its ability to continue as a going concern without additional funding. As of December 31, 2024, the accumulated deficit stood at approximately $21 million, underscoring the need for strategic financial management and potential capital raises to support ongoing operations and development efforts.